Table 2.
SS-13BN
|
SS
|
|||
---|---|---|---|---|
Normal | Hyper-caloric | Normal | Hyper-caloric | |
Emax, % Increase in Force | ||||
AngII | 71±10 (10) | 53±11(10) | 133±11 (8)* | 43±5 (14)† |
+PEG-SOD | 55±6 (6)‡ | 27±7 (3)‡ | 53±17 (6)‡ | 16±2 (9)‡ |
+CATALASE | 88±13 (4) | 25±5 (4)‡ | 73±21 (5)‡ | 46±6 (12) |
+L-NAME | 114±15 (6)‡ | 51±6 (5) | 117±13 (5) | 91±11 (11)‡ |
KCl | 140±4 (12) | 114±9 (10)* | 156±9 (9) | 148±6 (14) |
| ||||
logEC50, [M] for AngII; EC50, [mM] for KCl | ||||
| ||||
AngII | −8.1±0.01 (11) | −8.2±0.1 (10) | −8.4±0.1 (11) | −8.1±0.1 (14) |
+PEG-SOD | −7.8±0.2 (6)‡ | −7.7±0.1 (3)‡ | −8.0±0.2 (5) | −7.9±0.1 (9) |
+CATALASE | −8.2±0.1 (4) | −8.1±0.2 (4) | −8.3±0.4 (5) | −8.1±0.1 (11) |
+L-NAME | −8.4±0.1 (6)‡ | −7.9±0.1 (5) | −8.7±0.3 (6) | −8.2±0.04 (11) |
KCl | 17.6±1.1 (10) | 28.8±3.1 (6)* | 20.3±1.3 (13) | 25.9±1.4 (8)† |
P<0.05 vs. untreated aortas from SS-13BN rats on normal diet;
P<0.05 vs. untreated aortas from SS rats on normal diet;
P<0.05 vs. corresponding untreated aortas. Number of rats is in parentheses.